Therapeutic vaccines for malignant brain tumors

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 753-761

  Gustafson, Michael P ^a   Knutson, Keith L ^b   Dietz, Allan B ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Dendritic cells; Glioblastoma multiforme; Immunotherapy; Malignant glioma; Vaccine

Indexed keywords

EID: 78650285638     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Aerts-Toegaert C, Heirman C, et al. 2007. CD83 expression on dendritic cells and T cells:Correlation with effective immune responses. Eur J Immunol, 37:686-95.
2. Bax M, García-Vallejo JJ, et al. 2007. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol, 179:8216-24.
3. Biernacki K, Prat A, et al. 2004. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1-and Th2-polarized lymphocytes. J Neuropathol Exp Neurol, 63:223-32.
4. Bonifaz LC, Bonnyay DP, et al. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med, 199:815-24.
5. Britten CM, Janetzki S, et al. 2008. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother, 57:285-8.
6. Bucciero A, Vizioli L, et al. 1990. Prognostic significance of lymphoid infiltration in cerebral malignant gliomas. J Neurosurg Sci, 34:145-8.
7. Buckner JC, Brown PD, et al. 2007. Central nervous system tumors. Mayo Clin Proc, 82:1271-86.
8. Cabuy E, de Ridder L. 2001. Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Archiv, 439:176-84.
9. Caruso, DA, Orme, LM, et al. 2004. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol, 6:236-46.
10. de Vries IJ, Lesterhuis WJ, et al. 2003. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res, 9:5091-100.
11. de Witt Hamer PC, van Tilborg AA, et al. 2008. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene, 27:2091-6.
12. Debnath J, Muthuswamy SK, et al. 2003. Morphogenesis and oncogenesis of MCF-10A mammary eptihelial acini grown in three-dimensional basement membrane cultures. Methods, 30:256-68.
13. Dhodapkar MV, Steinman, RM. 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8(c) regulatory T cells in vivo in humans. Blood, 100:174-7.
14. Dietz AB, Bulur PA, et al. 2000. Maturation of human monocyte-derived dendritic cells studied by microarray hybridization. Biochem Biophys Res Commun, 275:731-8.
15. El Andaloussi A, Lesniak, MS. 2006. An increase in CD4 CD25CCFOXP3F regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma mutliforme. Neuro-oncol, 8:234-43.
16. Fecci PE, Mitchell DA, et al. 2003. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol, 64:161-76.
17. Fecci PE, Mitchell DA, et al. 2006. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res, 66:3294-302.
18. Figdor, CG, de Vries IJ, et al. 2004. Dendritic cell immunotherapy:mapping the way. Nat Med, 10:475-80.
19. Fujii S, Shimizu K, et al. 2003. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med, 198:267-79.
20. Gomez GG, Kruse, CA. 2006. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol, 10:133-46.
21. Graf MR, Sauer JT, et al. 2005. Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas. J Neurooncol, 73:29-36.
22. Gustafson MP, Xu C, et al. 2006. Regulation of cell proliferation in a stratified culture system of epithelial cells from prostate tissue. Cell Tissue Res, 325:263-76.
23. Hirano N, Butler MO, et al. 2006. Engagement of CD83 ligand induces prolonged expansion of CD8ppT cells and preferential enrichment for antigen specificity. Blood, 107:1528-36.
24. Hoos A, Parmiani G, et al. 2007. A clinical development paradigm for cancer vaccines and related biologics. J Immunother, 30:1-15.
25. Ifergan I, Kebir H, et al. 2008. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain, 131:785-99.
26. Jonuleit H, Kuhn U, et al. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 27:3135-42.
27. Katoh M, Wilmotte R, et al. 2003. Survivin in brain tumors:an attractive target for immunotherapy. J Neurooncol, 64:71-6.
28. Keilholz U, Martus P, et al. 2006. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res, 12:2346s-52s.
29. Kiertscher SM, Roth, MD. 1996. Human CD14KKleukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol, 59:208-18.
30. Kikuchi T, Akasaki Y, et al. 2004. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother, 27:452-9.
31. Kikuchi T, Akasaki Y, et al. 2002. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother, 51:424-30.
32. Knutson KL, dela Rosa C, et al. 2006. Laboratory analysis of T-cell immunity. Front Biosci, 11:1932-44.
33. Knutson KL, Disis, ML. 2005. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother, 54:721-8.
34. Kusmartsev S, Gabrilovich, DI. 2006. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother, 55:237-45.
35. Lapteva N, Seethammagari MR, et al. 2007. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res, 67:10528-37.
36. Lee J, Kotliarova S, et al. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9:391-403.
37. Liau LM, Prins RM, et al. 2005. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res, 11:5515-25.
38. Liu G, Akasaki Y, et al. 2005. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene, 24:5226-34.
39. Liu G, Yu JS, et al. 2004. AIM-2:a novel tumor antigen is expressed and presented by human glioma cells. J Immunother, 27:220-6.
40. Northwest Biotherapeutics, Website 2007. DCVax®-Brain Phase II Clinical Trial.
41. O'Neill DW, Adams S, et al. 2004. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood, 104:2235-46.
42. Ogden AT, Horgan D, et al. 2006. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosur, 59:902-10.
43. Ozawa T, Gryaznov SM, et al. 2004. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro Oncol, 6:218-26.
44. Panoskaltsis N, Reid CD, et al. 2004. Immune modulation with dendritic cells. Transfus Med, 14:81-96.
45. Pellegatta S, Poliani PL, et al. 2006. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cellmediated immune response against malignant gliomas. Cancer Res, 66:10247-52.
46. Pickl WF, Majdic O, et al. 1996. Molecular and functional characteristics of dendritic cells generated from highly purified CD14CCperipheral blood monocytes. J Immunol, 157:3850-9.
47. Prins RM, Scott GP, et al. 2002. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother, 51:190-9.
48. Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med, 353:1711-23.
49. Rutkowski S, De Vleeschouwer S, et al. 2004. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer, 91:1656-62.
50. Sallusto F, Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 179:1109-18.
51. Simpson JE, Newcombe J, et al. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol, 84:238-49.
52. Steiner HH, Bonsanto MM, et al. 2004. Antitumor vaccination of patients with glioblastoma multiforme:a pilot study to assess feasibility, safety, and clinical benefit. J Clinl Oncol, 22:4272-81.
53. Steinman RM, Nussenzweig, MC. 2002. Avoiding horror autotoxicus:The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A, 99:351-8.
54. Stupp R, Mason WP, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352:987-96.
55. Tacken PJ, de Vries IJ, et al. 2007. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol, 7:790-802.
56. Tang J, Flomenberg P, et al. 2005. Glioblastoma patients exhibit circulating tumor-specific CD8ttT cells. Clin Cancer Res, 11:5292-9.
57. Ueda R, Low KL, et al. 2007. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med, 5:68.
58. van den Heuval MM, van Beek NM, et al. 1999. Glucocorticoids modulate the development of dendritic cells from blood precursors. Clin Exp Immunol, 115:577-83.
59. van Duin D, Medzhitov R, et al. 2006. Triggering TLR signaling in vaccination. Trends Immunol, 27:49-55.
60. Wakkach A, Fournier N, et al. 2003. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity, 18:605-17.
61. Wheeler CJ, Das A, et al. 2004. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res, 10:5316-26.
62. Woiciechowsky C, Asadullah K, et al. 1998. Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma:Effect of tumor extirpation. J Neuroimmunol, 84:164-71.
63. Yajima N, Yamanaka R, et al. 2005. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res, 11:5900-11.
64. Yamanaka R, Abe T, et al. 2003. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer, 89:1172-9.
65. Yamanaka R, Homma J, et al. 2005. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma:results of a clinical phase I/II trial. Clin Cancer Res, 11:4160-7.
66. Yu JS, Liu G, et al. 2004. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res, 64:4973-9.
67. Yu JS, Wheeler CJ, et al. 2001. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res, 61:842-7.
68. Yuile P, Dent O, et al. 2006. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. J Clin Neurosci, 13:747-51.
69. Zhang X, Wang W, et al. 2005. Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer screening and testing. Biotechnol Prog, 21:1289-96.
70. Zhou LJ, Tedder TF. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin family. J Immunol, 154:3821-35.
71. Zhou LJ, Tedder TF. 1996. CD14ZZblood monocytes can differentiate into functionally mature CD83ffdendritic cells. Proc Natl Acad Sci U S A, 93:2588-92.